Gender differences in clinical presentation and outcomes of epidemic kaposi sarcoma in Uganda

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Phipps, Warren ^a,b   Ssewankambo, Fred ^c   Nguyen, Huong ^a   Saracino, Misty ^a   Wald, Anna ^a,b   Corey, Lawrence ^a,b   Orem, Jackson ^d,e   Kambugu, Andrew ^c   Casper, Corey ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Infectious Diseases Institute   (Uganda)

^d UGANDA CANCER INSTITUTE   (Uganda)

^e MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIC; FACE; FEMALE; HARD PALATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SKIN DEFECT; SKIN EDEMA; UGANDA; ADOLESCENT; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; STATISTICS;

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; EPIDEMICS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; SARCOMA, KAPOSI; SEX FACTORS; UGANDA; YOUNG ADULT;

EID: 78649747307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013936     Document Type: Article

References (33)

1. Onyango JF, Njiru A (2004) Kaposis sarcoma in a Nairobi hospital. East Afr Med J 81: 120-123.
2. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F (1999) AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13: 2563-2570.
3. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S (2000) Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 82: 1585-1592.
4. Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, et al. (2000) Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. Int J Cancer 85: 54-59.
5. Mwanda OW, Fu P, Collea R, Whalen C, Remick SC (2005) Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Ann Trop Med Parasitol 99: 81-91.
6. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, et al. (2006) Spectrum of cancers among HIV-infected persons in Africa: The Uganda AIDS-Cancer Registry Match Study. International Journal of Cancer 118: 985-990.
7. Wang J, Stebbing J, Bower M (2007) HIV-associated Kaposi sarcoma and gender. Gend Med 4: 266-273.
8. Nasti G, Serraino D, Ridolfo A, Antinori A, Rizzardini G, et al. (1999) AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients. J Acquir Immune Defic Syndr Hum Retrovirol 20: 337-341.
9. Lassoued K, Clauvel JP, Fegueux S, Matheron S, Gorin I, et al. (1991) AIDS-associated Kaposi's sarcoma in female patients. AIDS 5: 877-880.
10. Benedetti P, Greco D, Figoli F, Tirelli U (1991) Epidemic Kaposi's sarcoma in female AIDS patients-a report of 23 Italian cases. AIDS 5: 466-467.
11. Cooley TP, Hirschhorn LR, O'Keane JC (1996) Kaposi's sarcoma in women with AIDS. AIDS 10: 1221-1225.
12. Mosam A, Hurkchand HP, Cassol E, Page T, Cassol S, et al. (2008) Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS 19: 400-405.
13. Meditz AL, Borok M, MaWhinney S, Gudza I, Ndemera B, et al. (2007) Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr 44: 306-308.
14. WHO. Obesity: preventing and managing the global epidemic. Report on a WHO Consultation on Obesity, Geneva, 3-5 June, 1997. Technical Report Series Number 894.; 2000; Geneva. World Health Organization.
15. Karnofsky DA BJ (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: CMM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press. pp 199-205.
16. Krown S, Testa M, Huang J (1997) AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 15: 3085-3092.
17. Krown SE, Metroka C, Wernz JC (1989) Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7: 1201-1207.
18. Lunardi-Iskandar Y, Bryant JL, Zeman RA, Lam VH, Samaniego F, et al. (1995) Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 375: 64-68.
19. Gill PS, Lunardi-Ishkandar Y, Louie S, Tulpule A, Zheng T, et al. (1996) The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 335: 1261-1269.
20. Tavio M, Nasti G, Simonelli C, Vaccher E, De Paoli P, et al. (1998) Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma. Eur J Cancer 34: 1634-1637.
21. Rabkin CS, Chibwe G, Muyunda K, Musaba E (1995) Kaposi's sarcoma in pregnant women. Nature 377: 21; author reply 22.
22. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661.
23. Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, et al. (2009) Impact of HIV Infection and Kaposi Sarcoma on Human Herpesvirus-8 Mucosal Replication and Dissemination in Uganda. PLoS One 4: e4222.
24. Laney AS, Cannon MJ, Jaffe HW, Offermann MK, Ou CY, et al. (2007) Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. Aids 21: 1541-1545.
25. Laney AS, Dollard SC, Jaffe HW, Offermann MK, Spira TJ, et al. (2004) Repeated measures study of human herpesvirus 8 (HHV-8) DNA and antibodies in men seropositive for both HHV-8 and HIV. Aids 18: 1819-1826.
26. Smith MS, Bloomer C, Horvat R, Goldstein E, Casparian JM, et al. (1997) Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeficiency virus-positive patients and correlation with serologic measurements. J Infect Dis 176: 84-93.
27. Alagiozoglou L, Morris L, Bredell H, Martin DJ, Sitas F (2003) Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect 131: 1125-1129.
28. Ziegler J, Newton R, Bourboulia D, Casabonne D, Beral V, et al. (2003) Risk factors for Kaposi's sarcoma: a case-control study of HIV- seronegative people in Uganda. Int J Cancer 103: 233-240.
29. Casper C, Redman M, Huang ML, Pauk J, Lampinen TM, et al. (2004) HIV Infection and Human Herpesvirus-8 Oral Shedding Among Men Who Have Sex with Men. J Acquir Immune Defic Syndr 35: 233-238.
30. Gandhi M, Koelle DM, Ameli N, Bacchetti P, Greenspan JS, et al. (2004) Prevalence of human herpesvirus-8 salivary shedding in HIV increases with CD4 count. J Dent Res 83: 639-643.
31. Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, et al. (2009) Impact of HIV Infection and Kaposi Sarcoma on Human Herpesvirus-8 Mucosal Replication and Dissemination in Uganda. PLoS ONE 4: e4222.
32. Yoo D, Lee K, Munderi P, Sin K, Lee J (2005) Clinical and bronchoscopic findings in Ugandans with pulmonary Kaposi's sarcoma. Korean Journal of Internal Medicine 20: 290-294.
33. WHO (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available: http://www.who.int/hiv/pub/arv/advice/en/index.html. Accessed 2010 Jun 28.